ALFA Finder| Revenue growth | 5.8% YoY to Rs152 Cr |
|---|---|
| Margins | EBITDA margin 26.0% vs 25.0%; gross margin 62.6% vs 57.7% |
| Demand visibility | Reagents +19%, trade +20%; instrument orders disrupted |
| Management confidence | Confident initiatives will reinforce fundamentals and long-term value |
Growth
Reagents +19.23%, trade +20.13%, government stable; instruments -29.71% on consignee issues. Depreciation rose on Unit 4 capitalisation.
Outlook
Unit 4 fully operational in H2 FY27; 36 product licences; proposed 70% Heidelco Medicore acquisition. No quantitative guidance given.
Risks
Instrument execution weakness, government consignee availability, higher depreciation and finance cost, Unit 4 regulatory approval delays, prior-year one-time tax write-back.
Investor Presentation filed with NSE, NSE: QLINE. Summary written with AI assistance from the document.
Q-Line Biotech Ltd: key numbers
- Share price
- ₹488.30
- Market cap
- ₹1,139 Cr
- Revenue (annual)
- ₹341.7 Cr
- Net profit (annual)
- ₹55.72 Cr
- P/E (TTM)
- 20.4×Sector 55.1×
- Promoter holding
- 67.51%
- FII holding
- 0.87%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Q-Line Biotech Ltd
All →Q-Line Biotech Acquisition Worth ₹26.64 Cr
Q-Line Biotech agreed to buy 70% of unlisted Heidelco Medicore for Rs.26.64 Crore in cash. The target becomes a subsidiary through this related-party acquisition.
- Value
- ₹26.64 Cr
- Execution
- Maximum three months from signing of SPAs, extendable by mutual agreement
Q-Line Biotech Other Announcement
Q-Line Biotech filed its IPO monitoring agency report for the half year to September 2026. It flags Rs. 0.97 crore of prepayment charges paid from issue proceeds.
Q-Line Biotech Results Update
Q-Line Biotech's H1 FY27 revenue rose 5.83% while EBITDA grew 10.02%, but PAT fell 8.06%. The release also covers a proposed 70% stake acquisition in Heidelco.
Q-Line Biotech H1 FY27 Results: Net Profit ₹19.6 Cr, Down 8.0% YoY
Q-Line Biotech Ltd reported revenue from operations of ₹152.2 Cr (+5.8% YoY) and net profit of ₹19.6 Cr (-8.0% YoY) for H1 FY27.
- Key figure
- Net profit ₹19.6 Cr · -8.0% YoY
Q-Line Biotech Legal & Regulatory
Q-Line Biotech's board said a Rs.10,000 NSE fine for late XBRL voting-results filing was due to a portal glitch and requested a waiver. The total payable including GST is Rs.11,800.
- Value
- ₹0.01 Cr
Q-Line Biotech Board Meeting Date
Q-Line Biotech clarified a clerical error: its board meeting time is 4:15 PM, not 3:00 PM. The November 12, 2026 meeting will consider half-yearly financial results.